Control growth factor release using a self-assembled [polycation:Heparin] complex

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Zern, Blaine J ^a   Chu, Hunghao ^a   Wang, Yadong ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GLYCOSAMINOGLYCAN; GROWTH FACTOR; HEPARIN; POLY(ARGININATE GLYCERYL SUCCINATE); POLYCATION; UNCLASSIFIED DRUG; POLYAMINE; POLYCATIONS;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; PLASMA HALF LIFE; PRECIPITATION; PROTEIN SECRETION; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM;

FIBROBLAST GROWTH FACTOR 2; HEPARIN; MODELS, MOLECULAR; POLYAMINES;

EID: 77956217625     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011017     Document Type: Article

References (36)

1. Coultas L, Chawengsaksophak K, Rossant J (2005) Endothelial cells and VEGF in vascular development. Nature 438: 937-945.
2. Levi-Montalcini R (1987) The nerve growth factor 35 years later. Science 237: 1154-1162.
3. Carpenter G, Cohen S (1990) Epidermal growth factor. J Biol Chem 265: 7709-7712.
4. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, et al. (2002) The Molecular Biology of the Cell. 4 ed. New York, NY: Garland Science. 1616 p.
5. Guler HP, Zapf J, Schmid C, Froesch ER (1989) Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh) 121: 753-758.
6. Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, et al. (1990) Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. J Clin Invest 86: 1976-1984.
7. Sakiyama-Elbert SE, Hubbell JA (2000) Development of fibrin derivatives for controlled release of heparin-binding growth factors. J Control Release 65: 389-402.
8. Richardson TP, Peters MC, Ennett AB, Mooney DJ (2001) Polymeric system for dual growth factor delivery. Nat Biotechnol 19: 1029-1034.
9. Hsieh PC, MacGillivray C, Gannon J, Cruz FU, Lee RT (2006) Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 114: 637-644.
10. Xian W, Schwertfeger KL, Vargo-Gogola T, Rosen JM (2005) Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. J Cell Biol 171: 663-673.
11. Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC (1996) Heparin structure and interactions with basic fibroblast growth factor. Science 271: 1116-1120.
12. Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, et al. (1994) Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 79: 1015-1024.
13. Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL (2000) Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 407: 1029-1034.
14. Pellegrini L (2001) Role of heparan sulfate in fibroblast growth factor signalling: a structural view. Curr Opin Struct Biol 11: 629-634.
15. Ishihara M, Obara K, Ishizuka T, Fujita M, Sato M, et al. (2003) Controlled release of fibroblast growth factors and heparin from photocrosslinked chitosan hydrogels and subsequent effect on in vivo vascularization. J Biomed Mater Res A 64: 551-559.
16. Lopez JJ, Laham RJ, Carrozza JP, Tofukuji M, Sellke FW, et al. (1997) Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. Am J Physiol 273: H1317-1323.
17. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, et al. (2003) The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107: 1359-1365.
18. Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, et al. (2001) Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J 142: 872-880.
19. Sakiyama SE, Schense JC, Hubbell JA (1999) Incorporation of heparin-binding peptides into fibrin gels enhances neurite extension: an example of designer matrices in tissue engineering. FASEB J 13: 2214-2224.
20. Cai S, Liu Y, Zheng Shu X, Prestwich GD (2005) Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor. Biomaterials 26: 6054-6067.
21. Burdick JA, Ward M, Liang E, Young MJ, Langer R (2006) Stimulation of neurite outgrowth by neurotrophins delivered from degradable hydrogels. Biomaterials 27: 452-459.
22. Holland TA, Tabata Y, Mikos AG (2005) Dual growth factor delivery from degradable oligo(poly(ethylene glycol) fumarate) hydrogel scaffolds for cartilage tissue engineering. J Control Release 101: 111-125.
23. Cleland JL, Duenas ET, Park A, Daugherty A, Kahn J, et al. (2001) Development of poly-(D,L-lactide-coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. J Control Release 72: 13-24.
24. Guan J, Stankus JJ, Wagner WR (2007) Biodegradable elastomeric scaffolds with basic fibroblast growth factor release. J Control Release 120: 70-78.
25. Silva EA, Mooney DJ (2007) Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J Thromb Haemost 5: 590-598.
26. Takahashi Y, Yamamoto M, Yamada K, Kawakami O, Tabata Y (2007) Skull bone regeneration in nonhuman primates by controlled release of bone morphogenetic protein-2 from a biodegradable hydrogel. Tissue Eng 13: 293-300.
27. Nie T, Baldwin A, Yamaguchi N, Kiick KL (2007) Production of heparinfunctionalized hydrogels for the development of responsive and controlled growth factor delivery systems. J Control Release 122: 287-296.
28. Benoit DS, Anseth KS (2005) Heparin functionalized PEG gels that modulate protein adsorption for hMSC adhesion and differentiation. Acta Biomater 1: 461-470.
29. Hosaka A, Koyama H, Kushibiki T, Tabata Y, Nishiyama N, et al. (2004) Gelatin hydrogel microspheres enable pinpoint delivery of basic fibroblast growth factor for the development of functional collateral vessels. Circulation 110: 3322-3328.
30. Lee KW, Yoon JJ, Lee JH, Kim SY, Jung HJ, et al. (2004) Sustained release of vascular endothelial growth factor from calcium-induced alginate hydrogels reinforced by heparin and chitosan. Transplant Proc 36: 2464-2465.
31. Tanihara M, Suzuki Y, Yamamoto E, Noguchi A, Mizushima Y (2001) Sustained release of basic fibroblast growth factor and angiogenesis in a novel covalently crosslinked gel of heparin and alginate. J Biomed Mater Res 56: 216-221.
32. Jeon O, Kang SW, Lim HW, Hyung Chung J, Kim BS (2006) Long-term and zero-order release of basic fibroblast growth factor from heparin-conjugated poly(L-lactide-co-glycolide) nanospheres and fibrin gel. Biomaterials 27: 1598-1607.
33. Steffens GC, Yao C, Prevel P, Markowicz M, Schenck P, et al. (2004) Modulation of angiogenic potential of collagen matrices by covalent incorporation of heparin and loading with vascular endothelial growth factor. Tissue Eng 10: 1502-1509.
34. Seal BL, Panitch A (2003) Physical polymer matrices based on affinity interactions between peptides and polysaccharides. Biomacromolecules 4: 1572-1582.
35. Rajangam K, Behanna HA, Hui MJ, Han X, Hulvat JF, et al. (2006) Heparin binding nanostructures to promote growth of blood vessels. Nano Lett 6: 2086-2090.
36. Lee MK, Lander AD (1991) Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans: development of a sensitive electrophoretic approach. Proc Natl Acad Sci USA 88: 2768-2772.